Screening people with smoldering multiple myeloma for early amyloidosis
Checks for early light-chain amyloidosis in adults 40 or older with smoldering myeloma.
Plain-language title generated from the registry record
Registry title: Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Key facts
- Where
- Birmingham, Boston, Charlotte, Columbus, Dallas, Durham, Los Angeles, New York, Richmond, Salt Lake City, San Francisco, and Weston, United StatesSee the 13 sites
Where in United States
- University of Alabama HospitalBirmingham, United StatesTaking people
- Tufts Medical CenterBoston, United StatesTaking people
- Atrium Health Levine Cancer InstituteCharlotte, United StatesTaking people
- The Ohio State University Comprehensive Cancer CenterColumbus, United StatesTaking people
- UT Southwestern, Harold C. Simmons Comprehensive Cancer CenterDallas, United StatesNot yet recruiting
- UNC Lineberger Comprehensive Cancer CenterDurham, United StatesTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesTaking people
- Columbia University Irving Medical CenterNew York, United StatesTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
- VCU Medical CenterRichmond, United StatesTaking people
- University of Utah, Huntsman Cancer HospitalSalt Lake City, United StatesTaking people
- University of California San FranciscoSan Francisco, United StatesTaking people
- Cleveland Clinic Florida, Weston HospitalWeston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tufts Medical Center
- Trial code
- NCT06365060
- Record updated
- 26 October 2026
- Original description
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.Read full original descriptionShow less
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.
Inclusion: Patients 40 years of age and older; diagnosed with either Smoldering Multiple Myeloma or a Monoclonal Gammopathy; dFLC greater than 23 mg/L; abnormal FLC ratio; If the patient has an eGFR less than 50 mL/min/1.73m2, the FLC ratio is inconsequential. The patient only needs to meet the age and dFLC criterion.
Exclusion: Patients with a previous finding of amyloid in other biopsies will not be included; Patients younger than 40 years of age are not eligible; Adults unable to consent are not eligible, including the cognitively impaired Pregnant women, pregnant minors, minors (i.e., individuals who are not yet adults), wards of the state, non-viable neonates, neonates of uncertain viability, and prisoners are not eligible.